

# 1 **Untuned antiviral immunity in COVID-19 revealed by temporal type I/III** 2 **interferon patterns and flu comparison**

3  
4  
5 Ioanna-Evdokia Galani<sup>1,#</sup>, Nikoletta Rovina<sup>2,#</sup>, Vicky Lampropoulou<sup>1</sup>, Vasiliki Triantafyllia<sup>1</sup>, Maria  
6 Manioudaki<sup>1</sup>, Eleftherios Pavlos<sup>1</sup>, Evangelia Koukaki<sup>3</sup>, Paraskevi C. Fragkou<sup>4</sup>, Vasiliki Panou<sup>3</sup>, Vasiliki  
7 Rapti<sup>4</sup>, Ourania Koltsida<sup>5</sup>, Andreas Mentis<sup>6</sup>, Nikolaos Koulouris<sup>3</sup>, Sotirios Tsiodras<sup>4</sup>, Antonia Koutsoukou<sup>2</sup>  
8 and Evangelos Andreakos<sup>1,7,\*</sup>

9  
10 <sup>1</sup> Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research,  
11 Biomedical Research Foundation of the Academy of Athens, Athens, Greece

12 <sup>2</sup> ICU, 1<sup>st</sup> Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical  
13 School, 'Sotiria' General Hospital of Chest Diseases, Athens, Greece

14 <sup>3</sup> 1<sup>st</sup> Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical  
15 School, 'Sotiria' General Hospital of Chest Diseases, Athens, Greece

16 <sup>4</sup> 4<sup>th</sup> Department of Internal Medicine, Attikon University Hospital, University of Athens Medical School,  
17 Athens, Greece

18 <sup>5</sup> 2<sup>nd</sup> Respiratory Clinic, 'Sotiria' General Hospital of Chest Diseases, Athens, Greece

19 <sup>6</sup> Department of Microbiology, Hellenic Pasteur Institute, Athens, Greece

20 <sup>7</sup> Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London  
21 W2 1NY, United Kingdom

22  
23  
24 # These authors contributed equally to this work

25 \* Corresponding author, e.mail: [vandreakos@bioacademy.gr](mailto:vandreakos@bioacademy.gr)

26  
27 Keywords: COVID-19, interferon, viral infection, hyperinflammation, cytokine storm

## 30 **Abstract**

31 A central paradigm of immunity is that interferon (IFN) mediated antiviral responses precede the pro-  
32 inflammatory ones, optimizing host protection and minimizing collateral damage<sup>1,2</sup>. Here, we report  
33 that for COVID-19 this does not apply. By investigating temporal IFN and inflammatory cytokine  
34 patterns in 32 COVID-19 patients hospitalized for pneumonia and longitudinally followed for the  
35 development of respiratory failure and death, we reveal that IFN- $\lambda$  and type I IFN production is both  
36 diminished and delayed, induced only in a fraction of patients as they become critically ill. On the  
37 contrary, pro-inflammatory cytokines such as TNF, IL-6 and IL-8 are produced before IFNs, in all

38 patients, and persist for a prolonged time. By comparison, in 16 flu patients hospitalized for  
39 pneumonia with similar clinicopathological characteristics to COVID-19 and 24 milder non-hospitalized  
40 flu patients IFN- $\lambda$  and type I IFN are robustly induced, earlier, at higher levels and independently of  
41 disease severity, while pro-inflammatory cytokines are only acutely and transiently produced. Notably,  
42 higher IFN- $\lambda$  levels in COVID-19 patients correlate with lower viral load in bronchial aspirates and  
43 faster viral clearance, and a higher IFN- $\lambda$ :type I IFN ratio with improved outcome of critically ill  
44 patients. Moreover, altered cytokine patterns in COVID-19 patients correlate with longer  
45 hospitalization time and higher incidence of critical disease and mortality compared to flu. These data  
46 point to an untuned antiviral response in COVID-19 contributing to persistent viral presence,  
47 hyperinflammation and respiratory failure.

48

49

## 50 **Main**

51 Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one  
52 of the worst pandemics of our time, causing high incidence of pneumonia, acute respiratory distress  
53 syndrome (ARDS) and death<sup>3,4</sup>. One of the most notable features of SARS-CoV2 infection is that it goes  
54 unnoticed for a remarkably prolonged period of time, running a course of a mild or uncomplicated  
55 illness for weeks until sudden and severe symptoms develop, in a subgroup of patients, requiring  
56 hospitalization, oxygen support and/or admission to an intensive care unit (ICU)<sup>3,4</sup>. This is consistent  
57 with an unusually long incubation period of the virus, ranging from 2 to 14 days, and an unusually long  
58 presence of it in the respiratory tract, often being detectable for over a month after initial infection by  
59 conventional molecular diagnostic tests<sup>5,6</sup>. By comparison, influenza virus infection, the main  
60 respiratory virus accounting for pneumonia hospitalizations till now, has an incubation time of 1 to 4  
61 days, a short window of virus positivity of a few days, and an abrupt onset of symptoms causing  
62 pneumonia within 1-3 days<sup>7,8</sup>. Other frequent respiratory viruses such as respiratory syncytial viruses,  
63 rhinoviruses, parainfluenza viruses, metapneumonoviruses and regular human coronaviruses have also  
64 shorter incubation times (ranging from 1-5 days) and more rapid and acute manifestation of  
65 symptoms<sup>9</sup>, rendering SARS-CoV2 quite unique in that respect. The basis of this is unknown but is likely  
66 to be a key driver of the pathophysiology of COVID-19 underlying its distinctive disease course and  
67 clinical manifestations.

68 The hallmark of COVID-19 is the development of a hyper-inflammatory response, also known as  
69 'cytokine storm', impairing the gas-exchange function and leading to acute respiratory distress  
70 syndrome (ARDS), multi-organ failure and death<sup>10-12</sup>. We and others have previously shown that a  
71 finely tuned antiviral response, orchestrated by IFN- $\lambda$  (type III IFN) and type I IFN is critical for  
72 balancing immunity for optimal protection and minimal damage<sup>13-15</sup>. Deviation from this can unleash a  
73 detrimental 'cytokine storm' with devastating consequences for human health. A recent study  
74 suggested that in COVID-19 patients type I IFN and IFN- $\lambda$  are not produced as they could not be  
75 detected in the sera of a small COVID-19 cohort of otherwise unspecified clinical characteristics<sup>16</sup>. In  
76 contrast, another one reported that type I IFN is induced in COVID-19 patients, and indicated that their  
77 levels might be reduced in those that are critically ill<sup>17</sup>. Such discrepancy could be due to the fact that  
78 each of these studies focuses on a single and likely distinct snapshot of an apparently heterogeneous  
79 disease process. Therefore, pursuing kinetic analyses is pertinent to delineating the course of the

80 immune response, especially given that cytokines are transiently produced. This is particularly true for  
81 IFNs which are expressed early during infection and are rapidly down-regulated thereafter.

82 Here, we have performed a comprehensive temporal analysis of type I and type III IFN, and major  
83 inflammatory cytokine patterns in 32 COVID-19 and 16 influenza A virus infected (flu) patients  
84 hospitalized for community acquired pneumonia and longitudinally followed up according to current  
85 WHO guidelines<sup>18</sup>. Both groups of patients exhibited similar clinicopathological characteristics and  
86 comparable disease severity on admission (Table 1). We have also analyzed 24 milder flu patients with  
87 no radiological findings of pneumonia and no need for hospitalization (referred to as mild flu; Table 1),  
88 as well as 10 healthy individuals. Using high sensitivity Luminex and ELISA assays, we quantified 18  
89 cytokines and chemokines relevant to antiviral immunity and hyperinflammation in patient sera  
90 collected at defined time intervals following hospital admission (Fig. 1a and S1aa). This aligns patients  
91 on the basis of the same clinical criteria of disease symptoms and severity, mainly the presence of  
92 pneumonia and the requirement for oxygen support.

93 We found that COVID-19 patients had profoundly impaired induction of both IFN- $\lambda$  and type I IFNs.  
94 Median levels of IFN- $\lambda$  and type I IFNs were not detectable in most COVID-19 patients (Fig. 1b),  
95 although some patients made IFN- $\lambda$  and fewer of them also IFN- $\alpha$ . This contrasts flu patients who  
96 almost uniformly expressed both types of IFNs, within the first (day 1-3) time interval of admission,  
97 and at significantly higher levels. At all cases, IFN expression was transient, with type I IFN levels  
98 rapidly declining after the first three days of hospitalization, while IFN- $\lambda$  persisting longer.  
99 Interestingly, despite their limited ability to make IFNs, COVID-19 patients robustly expressed pro-  
100 inflammatory cytokines such as TNF, IL-6, IL-7, IL-8, IL-10, IFN- $\gamma$  and CCL3 that were maintained at high  
101 levels for a prolonged time (Fig. 1b). Other cytokines such as IL-1 $\beta$ , IL-12, IL-23 and CCL4 were also  
102 significantly up-regulated at specific time intervals compared to healthy individuals reflecting the  
103 heterogeneity of the disease course (Fig. S2).

104 A similar pattern emerged when comparisons were made according to disease symptoms onset (Fig.  
105 S1b). COVID-19 patients exhibited markedly delayed and reduced IFN- $\lambda$  and type I IFN levels which  
106 were detectable only in a fraction of the patients and from days 7-10 onwards of symptoms onset (Fig.  
107 S3, a-b). By comparison, all flu patients exhibited high levels during the first 6 days (Fig. S3, a-b).  
108 Although COVID-19 patients made little IFN during the first 6 days of symptom onset, they potently  
109 produced pro-inflammatory cytokines and chemokines such as TNF, IL-6, IL-8, IL-10 and CCL3 at levels  
110 similar to flu (Fig. S3, b-c). Moreover, they exhibited prolonged expression of pro-inflammatory  
111 mediators, with high levels of TNF, IL-6, IL-7, IL-8, IL-10 and CCL4 remaining detectable for over three  
112 weeks of onset, whereas in flu patients a number of these were by that time down-regulated (Fig. S3).

113 Notably, COVID-19 patients were admitted to hospital with similar markers of systemic inflammation  
114 such as CRP levels, white blood cell (WBC) and neutrophil counts, and neutrophil/lymphocyte (N/L)  
115 ratio to flu patients (Table 1 and Fig. S4, a-f). They even had lower fever and a lower CURB-65 score, a  
116 commonly used measure of pneumonia severity<sup>19</sup> (Fig. S4, g-h). However, during follow up COVID-19  
117 patients developed a much higher incidence of ARDS requiring ICU support. In our cohort, 16 out of 32  
118 patients (50%) developed critical disease, 3 of which died, compared to only 3 out of 16 flu patients  
119 (18.7%) none of which died (Fig. 2, a-b). Strikingly, COVID-19 patients became critically ill over a much  
120 broader time window (up to nine days after admission) than flu patients which manifested critical  
121 disease within the first day post admission. This is in agreement with the high incidence and protracted

122 course of severe respiratory failure described for COVID-19<sup>4,12</sup>. Interestingly, among COVID-19 patients  
123 those who became critically ill had higher CRP levels, WBC and neutrophil counts, and N/L ratio on  
124 admission (Fig. S4, a-f), but not CURB-65 or fever (Fig. S4, g-h and Table S1). Critically ill flu patients  
125 also had a tendency for higher WBC and neutrophil counts and a N/L ratio, as well as significantly  
126 raised CURB-65, whereas non-hospitalized flu patients did not exhibit any of these increases (Fig S4, a-  
127 h).

128 We thus examined whether temporal cytokine patterns differ between the various patient groups.  
129 Surprisingly, we observed that although COVID-19 patients that do not become critically ill produce  
130 little type I or III IFN, the ones that become critically ill make IFN- $\lambda$  which are significantly higher at the  
131 day 1-3 time interval compared to healthy and non-critically ill patients (Fig. 2c and S5). Some of the  
132 critically ill patients also make IFN- $\alpha$  (Fig. 2d and S5), albeit at significantly lower levels to mild non-  
133 hospitalized flu patients (Fig. 2d) or the total of hospitalized flu patients (both critically and non-  
134 critically ill;  $p < 0.05$ ). On the contrary, all COVID-19 patients make pro-inflammatory cytokines such as  
135 TNF, IL-6, IL-8, IL-10 and IFN- $\gamma$ , with critically ill patients exhibiting also higher levels of IL-6, IL-7 and  
136 TNF at specific time intervals, and a tendency for higher IFN- $\gamma$  consistent with the increased hyper-  
137 inflammatory state they are in (Fig. 2e, S5 and S6). Individual patient data further confirmed these  
138 trends (Fig. S7). Interestingly, CCL3 is significantly higher than healthy controls in non-critically ill  
139 COVID-19 patients but not in the critically ill ones (Fig. S6). By comparison, critically ill and non-  
140 critically ill flu patients did not differ in their ability to make type I and type III IFNs nor pro-  
141 inflammatory cytokines such as TNF, IL-6 or IL-7 (Fig. 2, c-e, S5 and S6). Similarly, non-hospitalized flu  
142 patients with mild disease exhibited strong production of type I and type III IFNs, indicating that across  
143 the spectrum of flu disease severity the antiviral response remains robust. Visualizing these patterns  
144 on radar plot reveals a major imbalance in the induction of antiviral and pro-inflammatory responses  
145 of COVID-19 patients that does not occur in flu (Fig. 2e).

146

147 We next sought to determine whether imbalanced cytokine patterns in COVID-19 patients are related  
148 to systemic immune effects, and parameters linked to disease severity. To that end, we obtained  
149 temporal white blood cell transcriptomes from 5 healthy individuals and 9 COVID-19 patients, 5 non-  
150 critically and 4 critically ill, starting from day 1 of entry to the ward or ICU and at different timepoints  
151 thereafter. In total, 24 comprehensive RNAseq gene expression datasets were analyzed, clustering  
152 according to the clinical phenotype and indicating this as the main source of variation (Fig. 3a and S8a).  
153 Focusing at day 1 as the most relevant timepoint, we found that 4225 genes were differentially  
154 expressed (DEGs) in COVID-19 patients compared to healthy individuals (Table S2). When critically and  
155 non-critically ill patients were compared separately to healthy controls, 4225 and 4902 DEGs were  
156 observed, respectively, of which 1979 were common whereas the rest were uniquely found in one or  
157 the other patient group (Fig. S8b, Table S2 and Table S3). Volcano plots pointed out notable  
158 differences in the most highly regulated genes between the groups with critically ill patients exhibiting  
159 a stronger immune and antiviral response gene patterns (Fig. S8, c-e). Pathway analysis of DEGs indeed  
160 revealed that the most significant pathways over-represented in critically ill patients were related to  
161 the positive regulation of the immune system, the activation of the innate immune response, the  
162 defense response to virus and the cellular response to IFN (Fig. 3b and Table S4). By contrast, in non-  
163 critically ill patients these pathways were not significant; the ones over-represented instead included  
164 the regulation of the cellular component size, IL-1 $\beta$  production and NK cell cytotoxicity (Fig. 3b).

165 Accordingly, heatmaps with temporal information unveiled the systemic activation of the innate  
166 immune response marked by the up-regulation of key pro-inflammatory genes and pattern recognition  
167 receptors (*C4bpa*, *Csf1*, *Il1rn*, *Cxcl10*, *Mmp8*, *Stat1*, *Ddx58/Rigi*, *Tlr4*, *Nlrp6*), and the induction of a  
168 dominant activated neutrophil-myeloid cell signature (*Mpo*, *Elane*, *Cd177*, *Itgam*, *Arg1*, *Ceacam8*,  
169 *Fcgr1a*) in the critically ill group that was milder and not significant in non-critically ill patients (Fig. 3,  
170 c-d). On the contrary, T and B lymphocyte lineage and related genes (*Cd3d*, *Cd3e*, *Cd4*, *Cd8a*, *Cd19*,  
171 *Cd22*) were markedly down-regulated in critically ill patients. These data are consistent with  
172 lymphopenia, high neutrophil counts, and a high N/L ratio also present in these patients (Fig. S4) and  
173 previously reported to be associated with more severe disease and worse outcomes in COVID-19  
174 patients<sup>3,4</sup>. Cytokines such as TNF, IL-6 and IL-8 may directly account for these effects, as they are well  
175 known to trigger the mobilization and activation of neutrophils, the development of lymphopenia and  
176 the induction of innate immune responses and systemic inflammation<sup>20,21</sup>. Notably, a long set of IFN-  
177 stimulated genes (ISGs) was also strongly induced in critically ill patients compared to only a fraction of  
178 them being up-regulated in the non-critically ill group (Fig 3e and S8f), in agreement with the patterns  
179 of IFN- $\lambda$  and type I IFN production in these patients. This cannot be attributed to differential  
180 expression of IFN receptors as no differences between *Ifnlr1*, *Il10rb*, *Ifnar1* and *Ifnar2* mRNA levels  
181 were observed among patient groups and healthy individuals with the exception of a 2-fold up-  
182 regulation of the already high levels of *Ifnar2* in critically ill patients (Table S2).

183 Interestingly, imbalanced cytokine patterns in COVID-19 patients with pneumonia were associated  
184 with a much worse disease outcome compared to flu. First, the COVID-19 group exhibited higher  
185 incidence of critical disease and mortality (Fig. 2b). Second, COVID-19 patients overall, as well as when  
186 grouped as critically and non-critically ill, required longer hospitalization time than their flu  
187 counterparts (Fig. 4, a-c). For non-critically and critically ill COVID-19 patients, median time was 14 and  
188 23 days, respectively, compared to flu that was 7 and 19 days (Fig. 4, b-c). Prolonged hospitalization  
189 could be attributed to the untuned antiviral responses, leading to a more protracted clinical course of  
190 COVID-19 relative to flu and a need for longer recovery even for the non-critically ill group. To identify  
191 cytokines and cytokine combinations that can predict hospitalization time and therefore be of  
192 prognostic value, we generated a correlation matrix of the cytokine levels at admission (days 1-3  
193 interval) and the duration of hospital stay (Fig. 4d). We found that higher IL-6 and IL-10, and lower  
194 CCL3 levels, are directly proportional to the duration of hospitalization (Fig. 4, d-f). The value of TNF  
195 and IL-6 as biomarkers for monitoring COVID-19 severity has been reported<sup>4,22,23</sup> but for CCL3 this is  
196 new. Interestingly, IFN- $\lambda$  levels also correlated with higher IL-6, and longer hospitalization, consistent  
197 with their almost exclusive induction in critically but not non-critically ill patients (Fig. 4d and 2c).

198 A question that arises is whether IFN levels induced in critically ill patients are beneficial as delayed  
199 type I or type III IFN production has been shown in animal models to cause immunopathology<sup>13,14,24</sup> or  
200 interfere with epithelial repair<sup>25,26</sup>, respectively. We found that higher IFN- $\lambda$  concentrations during ICU  
201 entry were associated with lower SARS-CoV2 viral load in the respiratory tract and faster viral  
202 clearance (Fig. 4, g-h). Moreover, a higher IFN- $\lambda$  to type I IFN ratio at that time was linked to a shorter  
203 stay in the ICU (Fig. 4i), with the two patients with the highest IFN- $\alpha$  levels also exhibiting the longest  
204 stay (both 23 days over a median of 17 days). These data suggest that delayed IFN- $\lambda$  induction may still  
205 be protective in critically ill COVID-19 patients whereas IFN- $\alpha$  may do more harm than good, at least in  
206 a subset of patients.

207 Taken together, our findings demonstrate that SARS-CoV2 infection does not follow the conventional  
208 paradigm of antiviral immunity. Instead of activating first the antiviral response followed by the pro-  
209 inflammatory process as a second line of protection, it does the opposite; it triggers the pro-  
210 inflammatory response long before IFN-mediated antiviral defenses are induced- if at all. This is a  
211 major paradox and helps explain many of the unique or unusual features of COVID-19. The long virus  
212 incubation time and persistence in the respiratory tract, giving positive SARS-CoV2 tests for weeks, can  
213 be attributed to the delayed and/or reduced production of type I and III IFNs. The absent or very mild  
214 symptoms of patients for an unusually extended period of time, can be attributed to the lack or  
215 impaired and delayed expression of type I IFNs, principal mediators of flu-like disease and symptoms  
216 such as runny nose, coughing, fatigue, dyspnea and fever in humans<sup>27</sup>. Finally, the early and persistent  
217 expression of pro-inflammatory cytokines culminating into prolonged hyper-inflammation can  
218 promote the sudden development of respiratory failure requiring hospitalization and frequently ICU  
219 admission. Noteworthy, in flu the swift induction of the type I and III IFN response, across the  
220 spectrum of disease severity, correlates with quicker recovery, and markedly lower incidence of critical  
221 disease or mortality<sup>13,24</sup>. The recent demonstration in a retrospective cohort study of 446 COVID-19  
222 patients that early administration of IFN- $\alpha$  (interferon-a2b) is linked to reduced in-hospital mortality  
223 whereas late IFN- $\alpha$  therapy leads to increased mortality and delayed recovery leaves little doubt that  
224 the timing of IFN production is also crucial in COVID-19 patients<sup>28</sup>. Conceivably, late production of type  
225 I or III IFN production might confer no viral resistance, but instead promote immunopathology.

226 Whether this unique clinical course of COVID-19 is related to the presence of SARS-CoV2-derived IFN  
227 inhibitors as previously proposed for SARS-CoV<sup>29,30</sup> and MERS-CoV<sup>31</sup> is not known but is a possibility. As  
228 with other viruses, inhibition may be overcome once higher viral loads are reached, e.g. after  
229 incubation of the virus and eventual spread in susceptible individuals. In our study, we did not see  
230 significant differences in virus levels between non-critically and critically ill patients at the time IFNs  
231 were measured (Fig. S9). However, higher virus load in severe over mild disease has been described in  
232 one study but not been confirmed in another<sup>32,33</sup>. Moreover, higher virus load can overcome SARS-  
233 CoV2 dose-dependent suppression of IFN production in cultured respiratory epithelial cells<sup>16</sup>.

234 Our study is not without caveats. First, it characterizes cytokine patterns in the circulation, and  
235 although these are commonly used to analyze 'cytokine storms' in response to infection, how well they  
236 correlate to immune responses in the respiratory tract is difficult to know. Second, it is relatively small,  
237 and our findings await validation in other cohorts. Still, our study is uniquely informative as it  
238 addresses the production of IFNs and the activation of the 'cytokine storm' in COVID-19 in a temporal  
239 manner, from hospital admission to ICU entry, and should therefore be particularly useful for the  
240 design of clinical trials testing IFN therapies. Finally, it provides a side-by-side comparison of COVID-19  
241 with flu, studying patient populations with similar genetic, demographic and clinicopathological  
242 characteristics, and therefore uncovers important differences in the antiviral immune response  
243 between these two diseases that have not been previously suspected.

244

## 245 **Methods**

246

### 247 **Study participants**

248 In this non-interventional study thirty two patients with diagnosis of COVID-19 pneumonia according to  
249 WHO guidelines and positive SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR)

250 testing on a respiratory sample (nasopharyngeal swab or bronchial aspirate) were included<sup>18</sup>. Patients  
251 were recruited between March and April 2020 from the 1<sup>st</sup> Respiratory and Critical Care Clinic ward and  
252 ICU of the “Sotiria” General Chest Diseases Hospital of Athens, Greece. Healthy, asymptomatic subjects  
253 with a negative SARS-CoV-2 RT-PCR at the time of inclusion served as the control group.

254 The severity of COVID-19 cases was classified based on the adaptation of the Seventh Revised Trial  
255 Version of the Novel Coronavirus Pneumonia Diagnosis and Treatment Guidance<sup>34</sup>. All patients had  
256 moderate to severe disease, and presented with respiratory symptoms and radiological findings of  
257 pneumonia. They met any of the following criteria:

- 258 1. Respiratory distress ( $\geq 30$  breaths/ min);
- 259 2. Oxygen saturation  $\leq 93\%$  at rest;
- 260 3. Arterial partial pressure of oxygen (PaO<sub>2</sub>)/ fraction of inspired oxygen (FiO<sub>2</sub>)  $\leq 300$  mmHg with no  
261 other organ failure.

262 Sixteen patients developed ARDS and critical illness due to respiratory failure (PaO<sub>2</sub>/FiO<sub>2</sub>  $\leq 200$   
263 mmHg) requiring mechanical ventilation, with shock and/or other organ failure necessitating intensive  
264 care unit (ICU) care.

265 Blood was drawn at various time intervals during hospitalization and at discharge; and white blood  
266 cells and plasma were collected and stored. Serum was also stored, almost daily, for further use.

267 In order to better understand the immune response of COVID-19 infection, subjects from a cohort of  
268 patients with confirmed H1N1/H3N2 influenza A virus (flu) infection were also studied. In total, 40  
269 patients were recruited at the 2<sup>nd</sup> Respiratory Clinic of the ‘Sotiria’ General Chest Diseases Hospital,  
270 Athens, Greece and the “Attikon” University Hospital, University of Athens Medical School, Athens,  
271 Greece. Confirmation was obtained from nasopharyngeal swabs using the BioFire  
272 FilmArray Respiratory Panel test (bioMerieux). Patients were categorized according to the severity of  
273 the disease into mild flu patients with no radiological findings of pneumonia, no need for oxygen  
274 support and hospitalization, and moderate to severe flu patients with radiological findings of  
275 pneumonia (x-ray or CT), oxygen need and symptoms requiring hospitalization. Hospitalized flu  
276 patients could be subdivided into patients that did not develop (PaO<sub>2</sub>/FiO<sub>2</sub>  $> 200$  mmHg) or developed  
277 critical disease (PaO<sub>2</sub>/FiO<sub>2</sub>  $\leq 200$  mmHg). Flu patients had similar clinico-pathological characteristics to  
278 COVID-19 patients upon admission (Table 1). All subjects included in the study were clinically  
279 evaluated and followed longitudinally during the whole period of hospitalization (from admission to  
280 discharge). All blood specimens were processed immediately for serum collection and aliquots were  
281 stored at  $-80^{\circ}\text{C}$ .

282 The study conforms to the principles outlined in the Declaration of Helsinki, and received approval by  
283 the Ethics Committees of the “Sotiria” General Chest Diseases Hospital, Athens, Greece (Approval  
284 numbers 16707/10-7-18 and 8385/31-3-20) and the “Attikon” University Hospital, University of Athens  
285 Medical School, Athens, Greece (Approval number 1821A/22-9-16).

286

### 287 **SARS-CoV-2 detection**

288 RNA was extracted from nasopharyngeal swabs and bronchial aspirates by using the Nuclisens easyMAG  
289 instrument (bioMerieux), according to the manufacturer’s instructions. Real time RT-PCR was performed  
290 on extracted nucleic acids targeting the E gene of SARS-CoV-2 as described by Corman et al<sup>35</sup>.

291

### 292 **Cytokine analysis**

293 Serum samples frozen and stored at  $-20^{\circ}\text{C}$ , without other thawing, were analyzed for the presence of  
294 IFN $\gamma$ , TNF, IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, IL-17A, IL-23, CCL3, CCL4 and CX3CL1

295 with the MILLIPLEX MAP Human High Sensitivity T cell Panel (Merck Millipore). Thawed serum aliquots  
296 were centrifuged at 13,000 rpm for 10 min at 4°C immediately prior to testing. Each assay was performed  
297 according to the manufacturer's protocol for serum samples, utilizing recommended sample dilutions  
298 and standard curve concentrations (Merck Millipore). Samples were analyzed on a Luminex 200™  
299 System according to the manufacturer's instructions (Merck Millipore). For each cytokine on each assay,  
300 the lowest detection limits were in pg/ml: 0.50 for IFN- $\gamma$ , 0.42 for TNF, 0.2 for IL-1 $\beta$ , 0.24 for IL-2, 0.60  
301 for IL-4, 0.16 for IL-6, 0.33 for IL-7, 0.30 for IL-8, 0.50 for IL-10, 0.24 for IL-12 (p70), 0.20 for IL-13, 0.50  
302 for IL-17A, 8.00 for IL-23, 2.00 for CCL3, 0.80 for CCL4 and 10.00 for CX3CL1. High sensitivity sandwich  
303 Enzyme-linked Immunosorbent Assay (ELISA) kits were used for the detection of human IFN- $\alpha$  (Thermo  
304 Scientific) and IFN- $\lambda$ 1 (Biolegend). Their sensitivity in pg/ml was 1.00 for IFN- $\alpha$  and 2.00 for IFN- $\lambda$ 1.

305

### 306 **RNAseq analysis**

307 For RNAseq analysis, total RNA was purified from whole blood leukocytes with the RNeasy Micro kit  
308 (Qiagen). RNA samples were treated with DNase I (Qiagen) and quantified on a NanoDrop (Thermo  
309 Scientific). NGS libraries were prepared with the TruSeq RNA Library Prep Kit v2 (Illumina) according to  
310 the manufacturer's instructions. Quality of the libraries was validated with an Agilent DNA 1000 kit run  
311 on an Agilent 2100 Bioanalyzer. Library samples were quantified using a Qubit™ dsDNA HS Assay Kit  
312 (Thermo Scientific) according to the manufacturer's instructions. Bar-coded cDNA libraries were  
313 pooled together in equal concentrations in one pool, and were sequenced on a NextSeq 500 System  
314 (Illumina) at the Greek Genome Center (Biomedical Research Foundation, Academy of Athens, Athens,  
315 Greece).

316

### 317 **Transcriptomics analyses**

318 Samples sequenced on NextSeq 500 (Illumina) were analyzed using standard protocols. Briefly, raw  
319 reads were pre-processed using FastQC v.0.11.2 and cutadapt v.1.6, and then mapped to the human  
320 genome (GRCh38) using the TopHat version 2.0.13, Bowtie v.1.1.1 and Samtools version v.1.1. The read  
321 count table was produced using HTSeq v.0.6. Following filtering of raw read counts with a threshold of  
322 10 in at least one dataset, resulting in a total of 21880 genes, DESeq2 analysis was performed<sup>36</sup>. This  
323 returned the log<sub>2</sub>foldchanges of the treatment compared to healthy individuals for each time point.  
324 Differentially expressed gene transcripts were selected based on an adjusted *p*-value cutoff of 0.05 (FDR  
325 5%). Pathway enrichment analysis was conducted using ClueGO and CluePedia plugin of Cytoscape.  
326 Heatmaps were performed using TM4 MeV v.4.8 and Euclidean distance was used for hierarchical  
327 clustering. Clustering and dendrograms were performed with hclust function and gg dendro package,  
328 respectively, in R.

329

### 330 **Data and software availability**

331 The raw RNAseq data have been deposited at GEO (<http://www.ncbi.nlm.nih.gov/geo/>) under  
332 BioProject accession number # PRJNA638753.

333

### 334 **Statistical analysis**

335 Data were analyzed on GraphPad Prism software. Statistical significance of differences was assessed  
336 using the Mann-Whitney *U* (MWW) test for non-parametric data. Associations between cytokines and  
337 hospitalization time (in days) were tested using Spearman rank-order correlation coefficient and



338 visualized using the corrplot R package. Polar charts from the ggplot2 R package were used for the  
 339 visualization of the differences in cytokine response patterns.

340

341 **Acknowledgements**

342 The authors would like to thank Dr A. Gavriil and G. Vatsellas for technical assistance, and Prof. P. Katsikis  
 343 and V. Soumelis for critically reading the manuscript. EA is supported by research grants from the  
 344 European Commission (IMMUNAID, No 779295 and CURE, No. 767015), the Hellenic Foundation for  
 345 Research and Innovation (INTERFLU, No 1574) and Janssen Pharmaceuticals. IEG is supported by a  
 346 research grant from the Hellenic Foundation for Research and Innovation (RELIEVE, No 506). This work  
 347 received also a donation from the J. Sanchez family and friends.

348

349 **Conflict of interest**

350 The authors declare that they have no conflict of interest.

351

352

353 **Tables**

354 **Table 1. Clinical, laboratory and imaging findings of the study patients on hospital admission**  
 355

Characteristics	COVID-19 Patients	FLU Patients	
	Moderate-to-severe, hospitalized (N=32)	Moderate-to-severe, hospitalized (N=16)	Mild, non-hospitalized (N=24#)
<b>Age</b>			
Median (IQR), yr	63 (49-77)	62.5 (52-73)	46 (31-50)
Age ≥65 yrs, no (%)	13 (41)	8 (50)	2 (8)
Male, no (%)	22 (69)	9 (56)	13 (54)
<b>Smoking history, no (%)</b>			
Never smoked	22 (69)	7 (44)	8 (40) (N=20)
Former smoker	4 (12)	3 (19)	1 (5) (N=20)
Current smoker	7 (22)	6 (37)	11 (55) (N=20)
<b>Coexisting disorder, no (%)</b>			
Any	19 (59)	13 (81)	10 (50) (N=20)
Diabetes	7 (22)	2 (12.5)	0 (0) (N=20)
Hypertension	12 (37.5)	8 (50)	2 (10) (N=20)
Cardiovascular disease	2 (6)	2 (12.5)	1 (5) (N=20)
COPD	0	6 (37.5)	2 (10) (N=20)
Asthma	3 (9)	1 (6)	0 (0) (N=20)
Cancer/Hematological malignancy	0 (0)/0 (0)	1 (6)/0 (0)	0 (0)/ 0 (0) (N=20)
Chronic renal disease	0 (0)	0 (0)	0 (0)
Overweight/Obese	17 (53)/8 (25)	N/A /2 (12.5)	N/A/ 0 (0)

Median interval from first symptoms on admission (IQR), days	5 (2-7)	1 (1-2.5)	2 (1-2) (N=16)
<b>Fever on admission</b>			
Patients, no/Total no (%)	12 (37.5)	16 (100)	19 (100) (N=19)
Median temperature (IQR), °C	37.5 (36.5-38.1)	38.5 (38.4-39)	38.6 (38.2-39)
<b>Symptoms on admission, no (%)</b>			
Dyspnea	21 (66)	N/A	N/A
Cough	20 (62)	11 (69)	8 (40) (N=20)
Fatigue	18 (56)	12 (75)	20 (100) (N=20)
Myalgia	4 (12)	8 (50)	13 (65) (N=20)
Diarrhea/ vomiting	6 (19)	4 (25)	4 (20) (N=20)
Median oxygen requirement (IQR, L/min)	3 (2-6)	9.5 (6-11)	0
CURB-65 score (IQR)	1 (0-2)	3 (1-3)	0
<b>Laboratory findings on admission</b>			
Leukocytes (IQR) x 10 <sup>9</sup> /L	6.40 (4.61-8.52)	7.27 (5.96-8.55)	5.85 (4.26-7.39) (N=16)
Neutrophils (IQR) x 10 <sup>9</sup> /L	5.65 (3.32-7.45)	5.08 (3.66-7.42)	4.26 (2.48-5.13) (N=16)
Lymphocytes (IQR) x 10 <sup>9</sup> /L	0.95 (0.54-1.37)	0.77 (0.59-1.48)	1.07 (0.72-1.42) (N=16)
Monocytes (IQR) x 10 <sup>9</sup> /L	0.40 (0.28-0.57)	N/A	N/A
Platelets (IQR) x 10 <sup>9</sup> /L	190 (131-242)	203 (180-242)	200 (164-227) (N=16)
CRP mg/dl, (IQR)	13.6 (3.64-19.4)	5.5 (1.65-12.6)	1.33 (0.82-2.40) (N=16)
Lactate dehydrogenase (LDH) (IQR), IU/L	334 (203-455)	300 (244-320)	215 (200-250) (N=16)
Alanine aminotransferase (ALT) >40 IU/L	29 (23-39)	27 (20-48)	16 (12-22.5) (N=16)
Ferritin (IQR), ng/ml	677 (395-1237)	N/A	N/A
PCT (IQR), ng/ml	0.08 (0.04 - 0.38)	N/A	0.06 (0.06-0.08) (N=10)
<b>Chest X-ray findings on admission</b>			
<b>Abnormal results, no (%)</b>	30 (94) <sup>##</sup>	15 (94) <sup>##</sup>	0 (0)
Unilateral infiltrates	4 (12.5)	5 (31)	0 (0)
Bilateral infiltrates	26 (81)	10 (63)	0 (0)

356 # In some cases, data available for fewer patients as indicated.

357 <sup>##</sup> X-ray negative patients were positive for unilateral or bilateral opacities on CT.

358 N/A: Not available

359

### 360 Figure legends

361 **Fig. 1: Temporal IFN and inflammatory cytokine patterns of COVID-19 and flu patients in relation to**  
362 **hospital admission. a,** Schematic showing the experimental design with sampling at specific time  
363 intervals after hospital admission of 32 COVID-19 and 16 flu patients with pneumonia. **b,** Levels of IFN-  
364  $\lambda$ 1, IFN- $\alpha$ , IFN- $\gamma$ , TNF, IL-6, IL-7, IL-8, IL-10 and CCL3 at various time intervals after hospital admission.  
365 Data are presented as scatter plots with dots showing individual patient measurements and columns  
366 median values with range. For COVID-19, n=16, 17, 21, 15, 11 and 8 for each of the six consecutive

367 time intervals. For flu, n=16, 14 and 11, respectively. For healthy, n=10. Grey shading marks the limit of  
368 quantification of the assay. *P* values were determined by a two tailed Mann–Whitney U test for non-  
369 parametric comparisons. \**P* < 0.05, \*\**P* < 0.01 and \*\*\**P* < 0.001 show significance over healthy  
370 controls. #*P* < 0.05, ##*P* < 0.01 and ###*P* < 0.001 show significance between COVID-19 and flu groups.

371

372 **Fig. 2: Comparison of IFN and inflammatory cytokine patterns between subgroups of COVID-19 and**  
373 **flu patients according to disease severity. a,** Schematic depicting the longitudinal follow up of 32  
374 COVID-19 and 16 flu patients hospitalized for pneumonia, and 24 non-hospitalized (N.H.) flu patients  
375 with no radiological findings of pneumonia. **b,** Incidence of critical disease in hospitalized COVID-19  
376 and flu patients over time. **c-d,** Levels of IFN- $\lambda$ 1 (c) and IFN- $\alpha$  (d) of critically and non-critically ill  
377 patients, and mild non-hospitalized patients at day 1-3 and 7-10 time intervals after hospital admission  
378 or visit, respectively, as well as healthy individuals. Dots show individual patient measurements and  
379 lines median values of hospitalized patients and healthy individuals. Squares show non-hospitalized flu  
380 patients. Grey shading marks the limit of quantification of the assay. **e,** Radar plots of median cytokine  
381 levels and range of hospitalized COVID-19 and flu patients developing critical versus non-critical illness,  
382 non-hospitalized flu patients and healthy individuals at the day 1-3 time interval after admission. Each  
383 circle in the radar plot represents logarithmically increasing concentrations from 4 to 256 pg/ml as  
384 shown in the healthy control. For days 1-3 n=9, 7, 24, 13 and 3 for each of the five consecutive groups,  
385 respectively. For days 7-10 n=8, 13, 15, 12 and 2, respectively. For healthy individuals, n=10. *P* values  
386 were determined by a two tailed Mann–Whitney U test for non-parametric comparisons. \**P* < 0.05,  
387 \*\**P* < 0.01 and \*\*\**P* < 0.001 show significance over healthy controls. #*P* < 0.05, ##*P* < 0.01 and ###*P* <  
388 0.001 show significance between COVID-19 and flu subgroups.

389

390 **Fig. 3: Kinetic analysis of blood transcriptional signatures of critically and non-critically ill COVID-19**  
391 **patients. a,** Principal component analysis of peripheral white blood cell transcriptomes of critically ill  
392 (n=4) and non-critically ill (n=5) patients or healthy (H1-H5) controls (n=5). **b,** Gene ontology (GO)  
393 pathway enrichment analysis of differentially expressed genes of all, critically ill and non-critically ill  
394 patients at day 1 of hospital or ICU entry. **c-e,** Heatmaps of differentially expressed innate immunity,  
395 leukocyte and IFN-stimulated genes and their kinetics following hospitalization of critically ill and non-  
396 critically ill COVID-19 patients compared to healthy controls. Data are expressed as log<sub>2</sub> fold values  
397 over healthy controls.

398

399 **Fig. 4: Correlation of IFN and cytokine expression patterns with disease outcomes. a-c,** Comparison  
400 of hospitalization time between COVID-19 and flu patients. All patients (a), patients with non-critical  
401 disease (b) and patients with critical disease (c) are shown. **d,** Correlation matrix of cytokine  
402 concentration levels at the day 1-3 time interval after hospital admission of COVID-19 patients  
403 indicating correlations between cytokines and total hospitalization time (TIME) or other cytokines. **e-f,**  
404 Correlation of IL-6 (e) and CCL3 (f) concentration levels with the duration of total hospitalization of all  
405 COVID-19 patients. **g,** Correlation of IFN- $\lambda$ 1 concentration levels with viral load expressed as CT values  
406 in bronchial aspirates collected at the same time interval as the sera used for IFN- $\lambda$ 1 quantification. **h,**  
407 Correlation of IFN- $\lambda$ 1 concentration levels with time required for viral clearance assessed as the first –

408 ve SARS-CoV2 test. i, Correlation of IFN- $\lambda$ 1:IFN- $\alpha$  ratio with the duration of hospitalization in the ICU.  
409 Dots show individual COVID-19 patient measurements and shaded dot plots values corresponding to  
410 COVID-19 patients becoming critically ill. *P* values were determined using the Spearman rank-order  
411 correlation coefficient for non-parametric data. \**P* < 0.05, \*\**P* < 0.01 and \*\*\**P* < 0.001

412

413

#### 414 **References**

- 415 1. Sen, G.C. Viruses and interferons. *Annu Rev Microbiol* **55**, 255-281 (2001).
- 416 2. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Garra, A. Type I interferons in infectious  
417 disease. *Nat Rev Immunol* **15**, 87-103 (2015).
- 418 3. Guan, W.J., *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*  
419 **382**, 1708-1720 (2020).
- 420 4. Huang, C., *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan,  
421 China. *Lancet* **395**, 497-506 (2020).
- 422 5. Wolfel, R., *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature*  
423 (2020).
- 424 6. Zheng, S., *et al.* Viral load dynamics and disease severity in patients infected with SARS-CoV-2  
425 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* **369**, m1443  
426 (2020).
- 427 7. Taubenberger, J.K. & Morens, D.M. The pathology of influenza virus infections. *Annu Rev*  
428 *Pathol* **3**, 499-522 (2008).
- 429 8. Paules, C. & Subbarao, K. Influenza. *Lancet* **390**, 697-708 (2017).
- 430 9. Lessler, J., *et al.* Incubation periods of acute respiratory viral infections: a systematic review.  
431 *Lancet Infect Dis* **9**, 291-300 (2009).
- 432 10. Mehta, P., *et al.* COVID-19: consider cytokine storm syndromes and immunosuppression.  
433 *Lancet* **395**, 1033-1034 (2020).
- 434 11. Wu, C., *et al.* Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in  
435 Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*  
436 (2020).
- 437 12. Yang, X., *et al.* Clinical course and outcomes of critically ill patients with SARS-CoV-2  
438 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet*  
439 *Respir Med* **8**, 475-481 (2020).
- 440 13. Galani, I.E., *et al.* Interferon-lambda Mediates Non-redundant Front-Line Antiviral Protection  
441 against Influenza Virus Infection without Compromising Host Fitness. *Immunity* **46**, 875-890  
442 e876 (2017).
- 443 14. Davidson, S., Crotta, S., McCabe, T.M. & Wack, A. Pathogenic potential of interferon alphabeta  
444 in acute influenza infection. *Nat Commun* **5**, 3864 (2014).
- 445 15. Andreakos, E., Zanoni, I. & Galani, I.E. Lambda interferons come to light: dual function  
446 cytokines mediating antiviral immunity and damage control. *Curr Opin Immunol* **56**, 67-75  
447 (2019).
- 448 16. Blanco-Melo, D., *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of  
449 COVID-19. *Cell* (2020).
- 450 17. Hadjadj, J., *et al.* Impaired type I interferon activity and inflammatory responses in severe  
451 COVID-19 patients. *Science* **369**, 718-724 (2020).
- 452 18. WHO. Clinical management of severe acute respiratory infections when novel coronavirus is  
453 suspected: What to do and what not to do. (WHO, 2020).
- 454 19. Lim, W.S., *et al.* Defining community acquired pneumonia severity on presentation to hospital:  
455 an international derivation and validation study. *Thorax* **58**, 377-382 (2003).

- 456 20. Galani, I.E. & Andreakos, E. Neutrophils in viral infections: Current concepts and caveats. *J*  
457 *Leukoc Biol* **98**, 557-564 (2015).
- 458 21. Mangalmurti, N. & Hunter, C.A. Cytokine Storms: Understanding COVID-19. *Immunity* **53**, 19-  
459 25 (2020).
- 460 22. Chen, G., *et al.* Clinical and immunological features of severe and moderate coronavirus  
461 disease 2019. *J Clin Invest* **130**, 2620-2629 (2020).
- 462 23. Liu, T., *et al.* The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.  
463 *EMBO Mol Med* (2020).
- 464 24. Channappanavar, R., *et al.* Dysregulated Type I Interferon and Inflammatory Monocyte-  
465 Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. *Cell Host Microbe*  
466 **19**, 181-193 (2016).
- 467 25. Broggi, A., *et al.* Type III interferons disrupt the lung epithelial barrier upon viral recognition.  
468 *Science* **369**, 706-712 (2020).
- 469 26. Major, J., *et al.* Type I and III interferons disrupt lung epithelial repair during recovery from  
470 viral infection. *Science* **369**, 712-717 (2020).
- 471 27. Wang, B.X. & Fish, E.N. The yin and yang of viruses and interferons. *Trends Immunol* **33**, 190-  
472 197 (2012).
- 473 28. Wang, N., *et al.* Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is  
474 Associated with Favorable Clinical Responses in COVID-19 Patients. *Cell Host & Microbe*, 1-10  
475 (2020).
- 476 29. Wathelet, M.G., Orr, M., Frieman, M.B. & Baric, R.S. Severe acute respiratory syndrome  
477 coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain.  
478 *J Virol* **81**, 11620-11633 (2007).
- 479 30. Kopecky-Bromberg, S.A., Martinez-Sobrido, L., Frieman, M., Baric, R.A. & Palese, P. Severe  
480 acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and  
481 nucleocapsid proteins function as interferon antagonists. *J Virol* **81**, 548-557 (2007).
- 482 31. Comar, C.E., *et al.* Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b  
483 Accessory Proteins during MERS Coronavirus Infection. *mBio* **10**(2019).
- 484 32. Liu, Y., *et al.* Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis* (2020).
- 485 33. He, X., *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med*  
486 **26**, 672-675 (2020).
- 487 34. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). *Chin*  
488 *Med J (Engl)* **133**, 1087-1095 (2020).
- 489 35. Corman, V.M., *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.  
490 *Euro Surveill* **25**(2020).
- 491 36. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for  
492 RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

493






FIG. 2




FIG. 3






FIG. 4